Trial Profile
Retrospective study of rivaroxaban and CYP3A4/P-gp interacting medications in Nonvalvular Atrial Fibrillation (NVAF) Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 May 2019
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Adverse reactions
- 22 May 2019 Results presented at the 24th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 15 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 91st Annual Scientific Sessions of the American Heart Association